Pharmacyclics (NASDAQ:PCYC) had its price target increased by Roth Capital from $144.00 to $151.00 in a research report sent to investors on Thursday morning, American Banking News.com reports. The firm currently has a buy rating on the stock.
Shares of Pharmacyclics (NASDAQ:PCYC) traded up 1.27% during mid-day trading on Thursday, hitting $123.78. The stock had a trading volume of 1,040,416 shares. Pharmacyclics has a 52 week low of $49.33 and a 52 week high of $143.34. The stock has a 50-day moving average of $126.5 and a 200-day moving average of $105.9. The company has a market cap of $9.054 billion and a P/E ratio of 118.90.
PCYC has been the subject of a number of other recent research reports. Analysts at JMP Securities raised their price target on shares of Pharmacyclics from $135.00 to $163.00 in a research note to investors on Thursday. They now have a market outperform rating on the stock. Separately, analysts at Wedbush reiterated an outperform rating on shares of Pharmacyclics in a research note to investors on Thursday. They now have a $165.00 price target on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of Pharmacyclics from $123.00 to $132.00 in a research note to investors on Friday, November 8th. They now have an outperform rating on the stock. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Pharmacyclics has an average rating of Buy and a consensus target price of $136.81.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.